We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CSL (CSL) is an Australian biotechnology company that specialises in blood plasmas, vaccines and anti-venoms. The world's largest collector of blood plasmas, CSL is also one of Australia's 5 biggest companies by market capitalisation. In 2020, it agreed to manufacture the AstraZeneca COVID-19 vaccine for the Australian government.
How to buy shares in CSL
Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
Search for CSL. Find the share by name or ticker symbol: CSL. Research its history to confirm it's a solid investment against your financial goals.
Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CSL reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
Check in on your investment. Congratulations, you own a part of CSL. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$291.37
1 month (2021-07-02)
2.53%
3 months (2021-05-03)
7.54%
Is CSL under- or over-valued?
Valuing CSL stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CSL's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
CSL's P/E ratio
CSL's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, CSL shares trade at around 36x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
CSL's EBITDA
CSL's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 billion.
The EBITDA is a measure of a CSL's overall financial performance and is widely used to measure a its profitability.
CSL financials
Revenue TTM
$10 billion
Operating margin TTM
34.5%
Gross profit TTM
$5.2 billion
Return on assets TTM
13.55%
Return on equity TTM
37.44%
Profit margin
26.7%
Book value
17.923
Market capitalisation
$131.5 billion
TTM: trailing 12 months
CSL's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like CSL.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
CSL's total ESG risk score
Total ESG risk: 27.73
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and CSL's overall score of 27.73 (as at 12/31/2018) is pretty good – landing it in it in the 40th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like CSL is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
CSL's environmental score
Environmental score: 3.04/100
CSL's environmental score of 3.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
CSL's social score
Social score: 18.57/100
CSL's social score of 18.57 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
CSL's governance score
Governance score: 11.12/100
CSL's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that CSL is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
CSL's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. CSL scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that CSL has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
CSL Limited was last rated for ESG on: 2019-01-01.
Total ESG score
27.73
Total ESG percentile
39.7
Environmental score
3.04
Environmental score percentile
5
Social score
18.57
Social score percentile
5
Governance score
11.12
Governance score percentile
5
Level of controversy
2
CSL share dividends
Dividend payout ratio: 33.48% of net profits
Recently CSL has paid out, on average, around 33.48% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.93% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CSL shareholders could enjoy a 0.93% return on their shares, in the form of dividend payments. In CSL's case, that would currently equate to about A$2.11 per share.
While CSL's payout ratio might seem fairly standard, it's worth remembering that CSL may be investing much of the rest of its net profits in future growth.
The latest dividend was paid out to all shareholders who bought their shares by 3 March 2021 (the "ex-dividend date").
Have CSL's shares ever split?
CSL's shares were split on a 3:1 basis on 17 October 2007. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CSL shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for CSL shares which in turn could have impacted CSL's share price.
CSL share price volatility
Over the last 12 months, CSL's shares have ranged in value from as little as $242 up to $318.8102. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while CSL's is 0.1328. This would suggest that CSL's shares are less volatile than average (for this exchange).
CSL overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Currently 0.184% of CSL shares are held by insiders and 28.411% by institutions.
CSL's fiscal year ends in June.
CSL's address is: 45 Poplar Road, Parkville, VIC, Australia, 3052
CSL's international securities identification number is: AU000000CSL8
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Gabi Byrnes is the Group Publisher for Banking & Wealth. She's a veteran of the digital media marketing industry, having worked within Ericsson's Broadcast and Media Services portfolio, and most recently at Mumbrella. She loves linking people to the right products and services to suit their financial goals. Gabi holds a Diploma in Financial Planning, and is RG146-accredited to provide advice in general insurance and basic deposit products.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Important information about this website
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder.com.au has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. You can learn more about how we make money here.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.
Please read our website terms of use and privacy policy for more information about our services and our approach to privacy.
